Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany

Mini Library

Discover new therapeutic utilities – get free access to a collection of our interesting R&D compounds
Our company is providing the Mini Library, comprising our former development or research compounds and derivatives thereof, within the framework of our Open Innovation Initiative free of charge to interested partners. We invite partners to use these compounds in their assay systems. Covering a wide range of different molecular targets (see below), these compounds might be of specific interest to you and your current research because they interact with and modulate the activity of an enzyme or receptor you are evaluating. Most of these are drug-like compounds that are not available otherwise.
The molecular targets comprise enzymes (e.g. kinases, phosphatases, proteases, cyclic nucleotide phosphodiesterases etc.), hormone or neurotransmitter receptors (serotonin, angiotensin II, endothelin, etc), transporters, ion channels and several others. All compounds are small organic compounds (no biologicals), which will be supplied in 50 µl of a 10 mM solution in dimethyl sulfoxide (DMSO) on a 96-well microtiter plate. In the first roll-out, the number of plates will be limited to 100.
A more detailed list of the target classes and the number of compounds per class in the Mini Library is available as download (login required) here.
Please read below how to apply and how to obtain the information on the structures of the compounds and their main biological activities.

We invite individuals from universities, research institutes and private companies to apply for obtaining a copy of our Mini Library.
In exchange for providing you with this unprecedented set of compounds, you agree to submit all data generated in your evaluation of these compounds to us. The legal, intellectual property and commercial aspects are covered in the “Mini Library Agreement” (see also: How to apply). Should we not be interested in using the results, you (and/or your institution) can use them subject to this agreement. Please note that intellectual property as covered in the agreement is distinct from inventorship.

The program is not open to U.S. healthcare providers.

Register to participate in the EMD Serono Mini Library initiative.

In your application you should describe the assay(s) in which you wish to test the compounds. You are asked to confirm that your submitted information is non-confidential in nature and that EMD Serono is allowed to use the information provided.

We will then review your application. In case of questions, you might be contacted by us and asked to clarify open issues in order to allow a proper decision. We will inform you within a time frame of four weeks after you have sent in your proposal on the results of the evaluation process.

If we approve your application, you (and/or your institution) are asked to sign the “EMD Serono Mini Library Agreement”.

After registration, you will have access to the Mini Library Agreement. Please note that the agreement has been set up and phrased in such a way as to be acceptable to as many partners as possible. We kindly ask you to accept the agreement “as is” as we cannot re-negotiate conditions on an individual basis.

In your proposal, you are asked to submit a short description of the assay(s) and anticipated targets for which you plan to test the compounds. You are welcome to describe the potential therapeutic use that could be derived from the outcome of your investigations. Please provide these data on a non-confidential basis.

We can accept or decline your application at our own discretion.

  • You will receive a unique set of compounds; most already have achieved a specific degree of maturity with regard to their characterization towards their targets as well as in vitro and in vivo effects (for some compounds even human data).
  • The collection contains some former development candidates (incl. clinical Phase II) for repurposing, including a full toxicological assessment package.
  • You can identify compounds that will be of help for your research.
  • You might also uncover new applications for these compounds when using them in an experimental setting in which they have not yet been investigated.
  • You get in contact with our experienced researchers to discuss your data and prepare the path to potentially start a joint drug discovery or development program.
  • The Mini Library is provided free of charge.
  • You can receive success payments on reaching certain milestones (for details see “Mini Library Agreement”).


Publication of Merck KGaA, Darmstadt, Germany.
There are two different, unaffiliated companies that use the name MERCK. Merck KGaA, Darmstadt, Germany, which operates this website, uses the firm name “Merck KGaA, Darmstadt, Germany,” in the United States and Canada, and also uses “EMD Serono” in biopharma, “MilliporeSigma” in life science and “EMD Performance Materials” in materials business. The other company, Merck & Co., Inc. holds the rights in the trademark MERCK in the United States and Canada. Merck & Co. is not affiliated with or related to Merck KGaA, Darmstadt, Germany, which owns the MERCK trademark in all other countries of the world.   To reflect such fact and to avoid any confusion, certain logos, terms and business descriptions of the publications on this website have been substituted or modified, such as by referring to “Merck KGaA, Darmstadt, Germany” instead of “Merck” standing alone.  Publications on this webpage, therefore, slightly deviate from the otherwise identical versions accessible outside the United States and Canada.


Please submit your
application by e-mail
Merck Serono Mini Library
Read more on M - The Explorer Magazine

Free-form displays in the cockpit

What was once known as the dashboard can now justifiably be called a cockpit: Our innovations for LC displays are opening up new dimensions that will also benefit automobile designers.

Read more on M - The Explorer Magazine
Read more on M - The Explorer Magazine

More safety: Smart automotive lighting

In cooperation with industrial partners such as Hella and Porsche, we are developing a headlight system that will improve traffic safety – thanks to liquid crystals shutters for sensitive responding.

Read more on M - The Explorer Magazine